NBI-98854

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
024620152017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The dopaminergic system plays a key role in the central nervous system, regulating executive function, arousal, reward, and motor… (More)
Is this relevant?
2017
2017
The vesicular monoamine transporter 2 (VMAT2) is an integral presynaptic protein that regulates the packaging and subsequent… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2017
2017
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… (More)
Is this relevant?
2017
2017
BACKGROUND Valbenazine (VBZ, NBI-98854) is a novel vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment… (More)
Is this relevant?
2017
2017
OBJECTIVE Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics… (More)
Is this relevant?
2017
2017
BACKGROUND The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind… (More)
Is this relevant?
Review
2017
Review
2017
OBJECTIVE The objective of this systematic review was to describe the efficacy, tolerability, and safety of valbenazine for the… (More)
Is this relevant?
Review
2016
Review
2016
Valbenazine (NBI-98854, Ingrezza) is a highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor that modulates… (More)
Is this relevant?
2015
2015
BACKGROUND Tardive dyskinesia is a persistent movement disorder induced by chronic neuroleptic exposure. NBI-98854 is a novel… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?